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Abstract 
In the last decade, advances in cancer immunotherapy, in all its facets, have 
revolutionized the way to treat cancer, becoming by now a pillar in the field of 
oncology. Immune checkpoint antibodies anti PD-1, PD-L1 and CTLA4 are 
successfully used in multiple types of cancer also as first-line therapy. 
Nevertheless, many patients do not respond to treatment or fall in continual 
relapse, which implies the need to boost anti-cancer immune response. 
Oncolytic viruses are a promising class of drug that counteract cancer both 
directly through cell lysis, and indirectly through recruitment of immune cells 
into the immunosuppressed tumour microenvironment. The clinical outcomes 
of recently approved Imlygic (Talimogene laherparepvec T-Vec) 
demonstrated, in a limited percentage of patients, an immune mediated anti-
tumour effect. Thus, as confirmed by preclinical and clinical evidences, the 
combination of immune checkpoint modulators and oncolytic viruses could 
represent a breakthrough in cancer immunotherapy field.  
The purpose of this study was to generate cancer immunotherapeutics based 
on next-generation oncolytic viruses, and a large repertoire of monoclonal 
antibodies targeting the main immune checkpoints. I generated a HSV-1 based 
OV with enhanced safety in normal cells and remarkable virulence in tumour 
cell lines. In a complementary manner, I isolated a large repertoire of hundreds 
of monoclonal antibodies through an ex vivo/in silico High Throughput 
Screening a of phage display library of human scFvs based on Next Generation 
Sequencing. This strategy allowed me to rapidly identify biological active 
mAbs targeting immune checkpoint modulators. Additional work will explore, 
in vivo, the most suitable combinations of engineered oncolytic viruses with 
immunomodulatory mAbs from our repertoire, in preclinical settings of 
investigation. 
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Introduction 
Oncolytic viruses 
General features of OV 
Oncolytic viruses (OV) are an emerging, large class of drugs for cancer 
treatments. The interest in viruses as anti-cancer drugs goes back to nearly a 
century, when important tumour regressions were observed as a consequence 
of naturally acquired viral infections. Thus, in 1912, an attenuated rabies virus 
was used in treatment of cervical carcinoma. Despite the interest, the first well 
established attempts to engineer viruses was reported in the '90s, thanks to the 
advances in technologies for genome manipulation and to the knowledge in 
viral biology. The first engineered OV reported by Martuza and colleagues was 
based on a thymidine kinase-negative mutant of Herpes simplex virus, which 
was demonstrated to prolong survival in a glioma nude mouse model [1]. After 
few years, Bischoff JR published a second vector, based on an adenoviral 
mutant, reporting a complete regression in over 60% of injected tumours in 
nude mice [2]. Despite these encouraging “historical” results, for years, the 
fragmented information about viral biology and tumour immunology have not 
allowed to get advantages from oncolytic virotherapy. Only in recent years 
OVs have entered clinical trials [3].  
An oncolytic virus is a viral particle able to infect and kill cancer cells without 
damaging healthy tissues. The viral progeny released from infected cells could 
spread and kill bystander tumour cells, but also endothelial cells, thus reducing 
tumour bulk, and acting as anti-vascular agent. However, the recent advances 
in oncoimmunology have shifted the way of seeing the virotherapy as an 
immunological drug, thanks to its ability to induce adaptive tumour-specific 
immune responses.  
An optimal OV should represent a good compromise between power and 
tumour selectivity, achievable in different ways, as it will be described below. 
To date, a plenty of naturally occurring or engineered viruses have been studied 
as oncolytics, including both enveloped (herpesviruses) and naked DNA 
(adenoviruses) and RNA viruses (i.e. Newcastle disease virus, measles). Many 
of these have entered early Phase I or II clinical trials as single drugs, or in 
combination therapies. Currently, there are about 80 completed or recruiting 
clinical trials, most of which with adenoviruses or herpesviruses, because of a 
deep knowledge in their biology [4,5]. Finally, in 2015 the Food and Drug 
Administration (FDA) and the European medicines agency (EMA) approved 
as first drug of this class the HSV-1 derived T-VEC (Imlygic, Amgen, 
Thousand Oaks, CA, USA) for the treatment of advanced melanoma lesions in 
the skin and lymph nodes. Much information is coming out from the clinical 
usage of T-VEC, shedding light on immunological relevance of the treatment. 
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OV as cancer vaccine: heating-up “cold” tumours 
Vaccines targeting cancer cells are in development from years. The goal of a 
cancer vaccine is to induce an effective adaptive immune response against 
tumour-associated antigens (TAAs). It has been reported that only a small 
percentage of tumours share common TAAs, suggesting the need for 
personalized, precision medicine. Classically, these cancer vaccines consist of 
ex vivo manipulated immune cells, tumour associated antigens (TAAs) 
(administered as recombinant proteins, coding vectors or cancer cell lysates). 
All these drugs have demonstrated efficacy both in pre-clinical and clinical 
contexts. In this scenario, OVs could represent a breakthrough. As previously 
hinted, it is well-established that the oncolytic virotherapy can induce both 
cellular and humoral anti-tumour immunity, working as a cancer 
immunotherapeutic. Indeed, tumour cells infected with an OV activate an 
inflammatory cascade, attracting immune cells for innate and adaptive immune 
responses against cancer. This feature is principally due to the immunogenic 
cell death (ICD) mechanisms induced by OVs, including immunogenic 
apoptosis, necrosis, necroptosis, pyroptosis, and autophagic cell death. The 
ICD is characterized by increased exposure of calreticulin on cell membrane, 
and release of well-known immune-related molecules such as uric acid, high-
mobility group box 1 and ATP. Moreover, viral infection induces the release 
of stimulating cytokines, such as IL-1, IL-6, IL-12, IL-18, IFN-γ. Along with 
these molecules, lysed cancer cells release TAAs and cancer related proteins 
(CRPs) arisen during cancer immunoediting. Then, antigen presenting cells 
(APC) capture both viral and tumour antigens and present them to naïve or 
anergic T cells. In this way, the immunocompromised tumour 
microenvironment (TME), characterized by overexpression of 
immunosuppressive and vascularization promoting cytokines like IL-10, TGF-
β, TNF-α and VEGFs, turns into an “immunocompetent habitat”. This effect 
is potentiated in “armed” OVs, in which immunostimulatory cytokines or 
chemokines like B7-1, IL-12, IL-18, IL-2, GM-CSF are encoded from 
engineered viral genomes [5-7] (Fig.1).  
According to their inflammatory status, tumours can be classified into three 
cancer-immune phenotypes: 
• Inflamed. This phenotype is characterized by the presence in tumour 
bulk of macrophages and tumour infiltrating lymphocytes (TILs) both 
CD4+ and CD8+, often specific for cancer cells, but anergic, because of 
the immune-suppressive microenvironment. This phenotype is suitable 
for immunomodulatory therapy.  
• Immune-excluded. The main feature of immune-excluded tumours are 
non-penetrating TILs, which are accumulated in the surroundings of 
tumour parenchyma. The clinical outcome of these patients is unclear. 
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• Immune-desert. In this class of tumours, TILs are totally absent or 
present in a very limited number. This phenotype is likely referred to 
those tumours with no pre-existing anti-tumour immunity. Immune 
checkpoint blockade is almost always useless [8]. 
 
Interestingly, OVs result both in strengthening of TILs in inflamed tumours 
and in induction of inflammation in those tumours with poor or completely 
absent immune cells. 
To date, the most reliable and used administration route of OVs is intra-tumour 
injection (IT). Indeed, even if the intravenous (IV) or intraperitoneal (IP) 
delivery may be preferred to get a systemic effect, IT administration avoids 
problems related to side effects and to eventual presence of neutralizing 
antibodies from pre-existing immunity against the virus. Despite many 
companies are dedicating efforts in advanced ways of systemic delivery 
(carrier cells, chelating molecules), emerging preclinical data are revealing a 
systemic effect of OVs also in IT injected patients. This feature of OVs has 
been confirmed by results from OPTIM trial (IT delivery of T-VEC) showing 
an important immune-mediated anti-cancer systemic effect. This phenomenon 
is known as abscopal, that is, the anti-tumour activity on distal uninjected 
lesions. In the beginning, this effect was thought to result from viral replication 
and spread from injected to uninjected tumours, but to date it has been 
demonstrated that in distal tumours there is no detection of virus. Recent data 
from T-VEC demonstrated the systemic immune response as a result of local 
IT activation of cancer specific T effector cells able to migrate towards distal 
lesions [9-11]. Unfortunately, the systemic “vaccine” effect on metastasis was 
not as potent as the OV injection in primary tumour, suggesting the need of 
combination therapies, as will be detailed in the next sections. 
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Fig. 1 Mechanisms of tumour cell death trough Oncolytic Viruses. The oncolytic 
virotherapy acts through several mechanisms. The box 1 shows the direct action of Oncolytic 
Viruses (OVs) through virus-mediated cell lysis. OVs infect and replicate in tumour cells, 
leading to direct cell death. The release of the progeny virus particles implies the infection of 
neighbour tumour cells, which results in the amplification of the initial viral input. The virus-
mediated cell lysis causes the release of Tumour-associated antigens (TAAs), Danger-
associated molecular patterns (DAMPs) and Pathogen-associated molecular patterns (PAMPs) 
that meet Antigen Presenting Cells (APCs), such as immature Dendritic Cells (DCs), leading 
to their maturation. This involves a local inflammation with the migration of mature DCs to 
lymph nodes, where they present TAAs and viral antigens to naïve T cells, leading to their 
maturation. The mature CD4+ and CD8+ T cells can thus induce an anti-cancer response acting 
on infected and uninfected tumour cells. This mechanism is represented in box 2, described as 
Anti-tumour immunity. In addition, as shown in box 3, the oncolytic virotherapy is able to 
induce the disruption of tumour vasculature by necrotic cell death, eliminating the fundamental 
structure for nutritional support of tumour cells [12]. 
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Herpes simplex viruses 
Herpesviruses are a large family of dsDNA, enveloped viruses, with a genome 
size ranging from 150 to about 250 kbp. According to the International 
Committee on Taxonomy of Viruses (ICTV), herpesviruses can be clustered 
in three main subclasses: 
• Alpha-herpesviruses, including herpes simplex virus type 1 (HSV-1) 
and herpes simplex virus type 2 (HSV-2) are characterized by a fast 
replicative cycle and prolonged latency in neurons. These viruses are 
able to infect most of vertebrates. 
• Beta-herpesviruses are characterized by slow replication targeting 
principally dendritic cells, macrophages, epithelial cells, endothelial 
cells, fibroblasts. The main members of this class are 
cytomegaloviruses (CMVs), human herpesvirus-6A and 6B (HHV-6), 
and human herpesvirus-7 (HHV-7) [13]. 
• Gamma-herpesviruses replicate slowly, similarly to beta-
herpesviruses; they become latent in lymphocytes, and can induce 
cellular transformation. Epstein-Barr virus (EBV) is the best 
characterized member of this class [14]. 
 
HSV-1 and HSV-2 are for sure the most prominent engineered herpesviruses 
used as oncolytics. 
 
 
HSV-1 structure and replication cycle  
HSV-1 has been the first isolated alpha-herpesvirus.  It is widespread all over 
the world with a prevalence range from 40 to 90% in developed and developing 
countries. Usually, it infects hosts through oral or genital mucosa. Rarely it is 
completely eradicated after contagion and primary infection; more often, 
through retrograde transport, it enters in a latent state of infection in sensory 
neurons. Occasionally, due to stress conditions or “spontaneously”, latent 
HSV-1 reactivates its replication, giving rise to new infective particles. HSV-
1 consists of an enveloped capsid with a size of about 150-200nm. From the 
inner to the external layers, we can distinguish: i) the icosahedral capsid 
containing the viral genome, ii) the tegument, consisting of viral proteins 
useful for viral entry, immediate early phase of HSV-1 infection and packaging 
(i.e. VP1/2, VP11/12, VP13/14, VP16, VP22), iii) the envelope, consisting of 
the more external coating of HSV-1, which contains all the glycoproteins 
required for viral entry in host cells (gB, gC gD, gH/L).  
HSV-1 genome is a linear dsDNA of about 152 kbp in length. Its genome 
consists of two unique sequences named unique long (Ul) and unique short 
(Us) flanked by inverted repeats. About 80 genes have been identified into the 
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HSV-1 genome by direct detection of transcripts and proteins or by open 
reading frame (ORF) predictions (Fig.2).  
HSV-1 entry is a multi-step process involving envelope glycoproteins and 
target host receptors. The first interaction is established between cell 
membrane proteoglycans like heparan sulfate (HS) and viral glycoprotein gC. 
This first unstable interaction is reinforced by gD which interacts with HSV-1 
preferential targets “herpes virus entry mediator” (HVEM) and nectin-1. 
Finally, host and viral membrane fusion is mediated by gH/gL complex. [15-
20] (Fig.3). Once membranes have been fused, the capsid crosses the cytosol 
through microtubules to the nucleus, where the viral genome is released. 
Recently, a novel alternative entry mechanism by endocytosis has been 
described [21]. 
Viral replication is a complex, tightly regulated mechanism. HSV-1 genes can 
be divided into three groups according to the post infection, temporal 
expression: immediate-early, early and late. The expression of immediate-
early (IE or α) genes is dependent on host transcriptional apparatuses and on 
the tegument protein VP16. The regulation of IE genes is the most complex 
among the transcriptional cascades involved in viral replication, due to 
composite consensus sequences upstream the core promoters recognized by 
viral trans activator VP16 and by the host cell proteins “coactivator host cell 
factor-1” (HCF-1) and Oct1. To date, five genes belonging to IE class have 
been identified. Of these, ICP4 and ICP27 are essential for complete viral 
replication. ICP4 is the major transcription regulator of HSV-1 for early and 
late viral genes. It acts both as an activating factor, inducing RNA Polymerase 
II transcription by recruiting the TFIID complex, as well as a repressor on its 
own promoter, according to a negative feedback [22]. ICP27 is required for 
maturation and cytosolic translocation of viral transcripts. Once IE genes have 
been activated, early genes can be transcribed and viral DNA replication starts, 
too. DNA replication occurs into the host nucleus from three origins of 
replication thanks to both host and viral apparatuses for DNA synthesis. 
Indeed, HSV-1 encodes its own apparatus for DNA replication including a 
helicase/primase complex (UL5, UL8, UL52), DNA polymerase and accessory 
proteins (UL30, UL42, ICP8 and UL29), and enzymes for nucleotide 
metabolism, including the well-characterized thymidine kinase (UL23) and 
others (UL39, UL40, UL50, UL2). After DNA replication, late genes are 
activated. One of the most characterized is ICP34.5, which is involved in 
reactivation of protein synthesis in infected host cells after PKR/eIF-2a axis 
activation. Eventually, HSV-1 particles are assembled starting from nucleus 
up to cell membrane passing through endoplasmic reticulum and Golgi 
apparatus (Fig.4) [23-25].  
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Fig. 2 Schematic representation of HSV-1 genome. The panel A shows in a colour-code the 
genes involved in DNA replication (yellow), regulation (red), viral assembly (green for capsid 
and light-blue for envelope proteins) and repeats regions (grey) [26]. 
The panel B shows the physical structure of a HSV-1 viral particle. Starting from the outer, 
the arrows indicate the envelope glycoproteins, capsid, tegument and the viral genome. The 
panel C shows the HSV genome, in details the distribution of Accessory (on top) and Essential 
(on bottom) genes. The essential genes are necessary for the replication in vitro, on contrary, 
the accessory genes can be deleted without influence the replication in vitro. The genes 
encoding glycoproteins and involved in pathogenesis are shown in parenthesis [27].  
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Fig. 3 Interaction of Herpes Simplex Virus entry receptors and their ligands. HSV 
displays on its surface five glycoproteins, gB, gC, gD, gH and gL responsible for its entry into 
host cells. gC and gB are involved in the initial attachment binding Heparan-sulphate 
glycoproteins. Moreover, gB binds Immunoglobulin-like type 2 receptor- α (PILRα), as shown 
in the first step of the picture. The gD glycoproteins binds herpesvirus entry mediator (HVEM), 
Nectin-1, Nectin-2 leading to a specific attachment and membrane fusion with the involvement 
of gH-gL heterodimer (second step). The viral-gene transcription occurs after the release of 
viral DNA into the host cell nucleus (third step) [28]. 
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Fig. 4 Cascade of immediate early, early and late genes transcription during the HSV-1 
infection. Starting from T0, the tegument protein VP16 induces the transcription of immediate 
early genes of HSV-1. These latter, namely ICP0, ICP4, ICP22, ICP27, induce the expression 
of early and late genes required for viral DNA replication and packaging. ICP4 regulation 
comprises a negative feedback on its own promoter. 
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HSV-1 as oncolytic virus 
HSV-1 is one of the most exploited viruses for oncolytic therapy, both 
preclinically and clinically [29]. It has a number of advantages, compared to 
other vectors: i) easy manipulation and large genome capacity for transgene 
expression, ii) good replication and power to kill majority of cancer cell types, 
iii) the entry and/or replication in normal cell can be limited by genetic 
engineering, iv) anti-viral drugs are available in case of “graft versus host” 
(Aciclovir & Ganciclovir). The main disadvantage of HSV-1 as an oncolytic 
virus is its high prevalence in population that could limit viral efficacy due to 
prior immunity and presence of neutralizing antibodies. However, during the 
phase I study of oncoVEX, it has been highlighted that pre-existing immunity 
(assessed as neutralizing antibodies in serum) seems not to affect clinical 
responses and outcomes [30,31].  
The most common manipulations of HSV-1 to get selective tumour clearance, 
saving normal cells, are attenuation and transcriptional or tropism retargeting. 
 
1) Attenuation of virus by mutation or deletions in one or more genes 
responsible for virulence. To this category belong viruses deleted or in 
UL39 gene, encoding ribonucleotide reductase ICP6, or in γ134.5. The 
main limitation of these OVs is amenable to attenuation of virulence 
both in normal and in tumour cells, limiting oncolysis. 
o ICP6 is required for dNTPs production and then DNA synthesis 
in neural cells, where deoxynucleotide availability is limited. 
HSV-1 Δ ICP6 can replicate only in those cells, like tumour 
ones, with high proliferative rate. 
o γ134.5 belongs to late timing genes of HSV-1 and it is present 
in double copy. As a consequence of viral infection, healthy 
cells activate protein kinase R (PKR) in response to IFNs. PKR 
inactivates, by phosphorylation, the translation initiation factor 
eIF2α, arresting total protein synthesis. ICP34.5 recruits 
phosphatase 1, reactivating eIF2α and protein synthesis. Since 
IFN pathway is often impaired in cancer, a HSV-1vector 
deleted in both copies of γ134.5 should replicate in tumour cells, 
sparing normal ones. Most of HSV-1 OVs in development and 
in clinical trial, including the approved T-VEC, are based on 
this deletion. Over the attenuated phenotype, this strategy 
suffers of a second limitation. The PKR inactivation in tumour 
cells is caused by MAPK/MEK pathway [32]. Despite MEK 
pathway is one of the main drivers of tumour growth, it is not 
active universally in cancer diseases. Moreover, tumour cells 
could acquire resistance to Δ ICP34.5 virotherapy by MEK 
silencing [33] 
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2) Transcriptionally retargeted (TR) viruses have been developed to 
overcome the problems related to attenuation of deleted OVs. In TR 
OVs, one or more viral genes are encoded under the control of a tumour 
related promoter, in order to get selectivity against cancer cells. To 
date, both accessory and essential viral genes have been exploited to 
achieve transcriptional retargeting. Two of the most preclinical 
relevant examples of TR HSV-1 OV are: i) rQNestinHSV-1 expressing 
ICP34.5 under control of Nestin promoter, which has been shown to be 
useful in preclinical models of Glioblastoma (GBM) and brain tumours 
[34], ii) oHSV1-hTERT expressing the essential gene ICP4 under the 
control of human telomerase reverse transcriptase (hTERT) gene 
promoter [35].  
 
3) The tropism retargeted viruses exploit the viral entry to achieve tumour 
selective viral infection. As previously described, herpesviruses entry 
in host cells is mediated by membrane glycoproteins. OVs of this class, 
combine the detargeting of glycoproteins (i.e. gD or gH) from natural 
receptors (i.e. HVEM or nectin-1) to retargeting to tumour membrane 
antigens. The retargeting can be obtained in different ways: 
- Peptide ligands fused to viral glycoproteins able to interact with 
tumour receptors. 
- Soluble adapters (i.e. HveC-scFv) as a bridge between gD and a 
target tumour protein. 
- Substitution of essential amino acids of glycoproteins gD or gH 
with a single chain antibody (scFv) targeting a tumour specific 
receptor or protein. With this approach Campadelli-Fiume and 
colleagues isolated non-attenuated, fully retargeted OVs targeting 
human HER2, demonstrating an important preclinical efficacy [36]. 
One potential limit of this approach, not well assessed by authors, 
could be the limited safety due to target receptor expression in 
healthy tissues (i.e. potential cardiac toxicity of a HER2 retargeted 
OV) (Fig.5). 
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Fig. 5 Schematic representation of engineered oncolytic viruses based on HSV-1. The 
boxes enclose the four main groups of oHSV-1 subdivided according to different strategies for 
tumour restricted replication. Attenuated viruses are characterized by deletion in Neurovirulent 
factor ICP34.5. In armed viruses, one or more viral genes are replaced with cytokines or 
Cyp2b1 cytochrome. Transcriptionally retargeted oHSVs are obtained by replacing viral 
promoter of essential genes with a tumour specific one. The tropism retargeted oHSV-1 
comprise variuos deletions of viral glycoproteins required for entry of HSV-1. The moieties 
deleted are usually replaced by scFv targeting a tumour antigen. Gray boxes symbolise the 
inverted repeats regions of HSV-1 genome. Deleted viral genes, in red, are marked as X. In 
green or blue are shown the transgenes encoded in selected location. HS: heparan sulfate 
binding site. pK: polylysine tract. TK: thymidine kinase. GM‐CSF: granulocyte‐macrophage 
colony‐ stimulating factor [33]. 
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Talimogene laherparepvec (T-VEC), from lab bench to bedside 
Talimogene laherparepvec, (T-Vec, tradenamed Imlygic™, formerly called 
OncoVexGM-CSF) has been the first OV approved by FDA and EMA for 
clinical uses. Its genome is deleted from both copies of γ34.5 (ICP34.5) and 
from α47 (ICP47) genes. In addition, T-VEC is armed with an expression 
cassette encoding the human granulocyte macrophage colony stimulating 
factor (hGM‐CSF) inserted into the deleted γ34.5 loci (Fig.6). ICP47 inhibits 
host TAP protein required for presentation of antigens in major 
histocompatibility complex class I (MHC I) [37]. This protein is used by the 
virus to “hide” its epitopes, to escape innate and adaptive immune system 
responses. The deletion of this gene in T-VEC allows to improve the cancer 
vaccine effect by increasing neoepitopes display on cell membrane in the 
context of MHC I. γ34.5 deletion, as previously described, is responsible for 
cancer-selective replication of attenuated herpesviruses. In situ GM-CSF 
production is aimed to enhance the activation of APCs (dendritic cells and 
macrophages) and, thus, of effector T cells. To compare the efficacy T-VEC 
(expressing GM-CSF) to a non-armed version, Hawkins and colleagues used a 
bilateral subcutaneous tumour mouse model. They demonstrated that despite 
both viruses could reduce the size of injected tumours, only GM-CSF 
expressing T-VEC induced an abscopal systemic effect on the contralateral 
lesion [38]. 
In an “exploratory” phase I clinical trial, T-VEC safety was demonstrated in 
various metastatic tumours including malignant melanoma, breast, head/neck 
and colorectal cancer with injectable metastasis in cutaneous, subcutaneous or 
lymph nodes. Notwithstanding neither complete nor partial responses were 
observed, a stable disease was reported in several patients. Moreover, a local 
inflammation was observed in injected tumours especially in seronegative 
patients. Therefore, T-VEC entered in phase II study for the treatment of 50 
patients with non-resectable stage III and IV melanoma. According to 
Response Evaluation Criteria in Solid Tumors (RECIST) the overall response 
rate was 26% (16% complete and 10% partial response). Interestingly, 
responses were observed both in injected and in uninjected lesions. In addition, 
it was reported an increased number of local and systemic CD8+ effector T 
cells combined to decrease in CD4+FoxP3+ Treg cells [39]. Finally, in a phase 
III clinical trial recruiting 436 patients with unresectable stage IIIB-IV 
melanoma, T-VEC efficacy was compared to subcutaneous injection of 
recombinant GM-CSF. The endpoints of this study were: i) the objective 
response to treatment according to World Health Organization (WHO) criteria 
defined durable response rate (DRR), ii) the secondary endpoints were 
progression-free, overall survival, objective response rate (ORR) and duration 
of response. The main points derived from this study were: i) the regression in 
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both injected (64% of which 47% complete response) and uninjected tumours 
(34% of non-visceral and 15% of visceral lesions) ii) the ORR of T-VEC was 
significantly higher (26%) than GM-CSF (5.7%). In spite of the encouraging 
results, no significant differences in median overall survival were observed in 
T-VEC treated patients compared to GM-CSF (23.3 T-VEC vs 18.9 GM-
CSF months) suggesting the need for further combinational studies. The 
mainly reported adverse effects of T-VEC treatment were fatigue and flu-like 
symptoms. Thanks to these results, in October 2015 FDA approved T-VEC for 
local treatment of unresectable melanoma, soon followed by EMA [40-42]. 
  
16 
 
 
Fig. 6 Schematic representation of Talimogene laherparepvec (T-VEC) genome. T-VEC 
is a genetically modified herpes simplex virus (HSV) type-1 encoding GM-CSF. The 
production of GM-CSF by infected tumour cells leads to a localized immune response 
strengthening anti-tumour effect. Both 34.5 regions were deleted and replaced with two 
expression cassettes constituted by Cytomegalovirus (CMV) promoter, human GM-CSF 
(hGM-CSF) and polyA (pA). Moreover, it was deleted also in ICP7 region, required for 
MHCI-display of intracellular antigens. 
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Cancer immunoediting 
Various lines of evidence have established that tumour cells and immune 
system establish a tug of war known as “Three E” (Elimination-Equilibrium-
Escape) of cancer immunoediting (Fig.7) [43,44]. According to this model, 
once a normal cell turns into a cancer one, immune system is able to recognise 
and eliminate it. Elimination is due to innate, but especially adaptive immune 
responses. Innate immune cells can directly or indirectly kill tumour cells. 
Natural killer (NK) cells are probably the main players of innate mechanisms 
for cancer cell recognition and elimination. NK can identify and kill tumour 
cells by various TNF family ligand-receptor interactions between NK and 
cancer cells (i.e. CD27, OX40, CD137), as well as NK can recognize and kill 
by perforin and granzyme B MHC I non-expressing cancer cells [45]. 
Dendritic cells (DC) as well as macrophages, are antigen presenting cells 
(APC) able to recognize “eat me” molecules expressed on apoptotic tumour 
cell surface, eliminating debris from apoptosis. In addition, APCs can be 
stimulated by cancer-related, damage-associated molecular patterns (DAMPs), 
among which DNA sensing by Toll-Like Receptors (TLRs) and STING 
pathways seem to be among the most effective. Activated APCs express T cells 
costimulatory molecules CD80/CD86 and migrate into lymphoid organs, 
where they act as a bridge between innate and adaptive immune responses, by 
presenting cancer related proteins and/or TAAs to naïve CD4 or CD8 T cells, 
respectively, by MHC II or MHC I complex [46]. Within lymph nodes, epitope 
landscape is probed by T cells through T cell receptor (TCR), inducing the 
priming and activation of reactive T cells. Activated effector T cells infiltrate 
the tumour bulk recognizing by specific TCR the cognate antigen displayed in 
MHC I context on tumour cells surface. It has been well established that 
cytotoxic cells play an essential role in anti-cancer immunity, whereby CD8 
cytotoxic T lymphocytes (CTLs) depletion (by αCD8 Ab) in tumour-bearing 
mice results in facilitated tumour growth. On the contrary, although the 
scientific community is dedicating great efforts to characterize immune cell 
subpopulations, conflicting reports abound about the CD4 T cells. For sure, 
CD4 T cells play an important role in the first activation and expansion of 
CTLs as well as they are crucial for maintenance of anti-tumour CD8 T cell 
memory. These features are principally attributable to the formation of the trio 
composed by CD4 and CD8 T cells bound to the same APC, respectively 
through MHC II and MHC I. In this complex, CD4 helper cells activate, by IL-
2, the neighbouring CD8 T cells physically associated to the same APC [47]. 
More recently, Bourgeois reported a non-canonical direct interaction between 
CD4 and CD8 T cells via CD40–CD154 (CD40L) in the generation of CD8 
memory cells [48]. In contrast, many reports point out that depletion of CD4 T 
cells (by αCD4 Ab) in tumour-bearing mice has strong anticancer effects. For 
sure, CD4 Treg subpopulation plays an essential physiological role in 
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inhibition of tumour-specific CTLs, but Ueha and colleagues demonstrated a 
stronger anti-tumour effect of total CD4 depletion compared to selective Treg 
(CD4, CD25, Foxp3+) abrogation [49]. Most likely, CD4 role in anti-tumour 
response is strongly time dependent. In the early immunoediting, CD4 cells are 
probably required for the full activation and expansion of CTLs, as well as they 
are required for development of memory T CD8 cells. On the contrary, at later 
stages, CD4 could limit tumour cell clearance by direct or indirect CTLs 
inhibition [50]. More recently, systematic studies from preclinical and clinical 
outcomes shed light on the importance of humoral immune response against 
cancer by TAA autoantibodies [51]. This process keeps cancer in check until 
Equilibrium phase. In this phase, sporadic transformed cells are spared by 
immune system due to adaptation, so that tumour cells acquire a “tumour 
dormancy” phenotype. In this condition cancer cells undergo genetic and 
epigenetic modifications driven by immune system pressure. A key role is 
probably assumed by pro- and anti-tumour cytokines balance. One of the main 
characterized pathways of equilibrium phase is the balance between the two 
dimeric cytokines IL-12 (anti-tumour) and IL-23 (pro-tumour) that share one 
of the dimer subunit, called p40. Despite the efforts, characterization of the 
Equilibrium phase is challenging and not fully understood. The continuous 
cancer immunoediting leads tumour cells to escape and indefinitely grow 
through several mechanisms: i) hiding TAAs by silencing mutated genes or 
MHC I down regulation, ii) acquiring resistance to apoptotic stimuli, iii) 
inducing T-cell anergizing microenvironment (see next sections) [52]. 
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Fig. 7 The cancer immunoediting theory. Cancer immunoediting is a complex process that 
regards the balance between immunosurveillance and cancer establishment. It consists of three 
sequential phases: elimination, equilibrium, and escape. During the elimination phase, innate 
and adaptive immunity destroy transformed cells. Despite the effectiveness of elimination, 
some tumour cells can escape this process and may then enter the equilibrium phase, in which 
the elimination of tumour cells is prevented by immunologic mechanisms. During this phase 
tumour cells undergo a selection process called immunoediting and may persist in this stage 
for years. The persisting tumour cells may then start to grow entering the escape phase. In this 
phase the tumour microenvironment is well-known to be immune compromised [44]. 
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Cancer immunotherapy 
The knowledge on the tight linkage between cancer and immune system, 
acquired during the last decades, has generated a new branch of cancer therapy 
known as immunotherapy. Based on the idea that immune system itself can 
counteract tumour progression, the aim of immunotherapy is to reactivate 
CTLs against cancer. The main approaches of immunotherapy are: 
• Adoptive cell therapy using autologous TILs. This approach consists 
of isolation and in vitro amplification of lymphocytes extracted from 
resected tumours by IL-2 supplemented media. Expanded T cells are in 
vitro tested for tumour cytotoxic activity and then reinfused into 
patients. To date, many clinical trials have demonstrated the 
effectiveness of this approach to induce complete and durable 
regressions of cancer disease [53]. 
• CAR-T cells. CAR-T cells are patients-derived engineered T 
lymphocytes able to recognize target cancer cells by MHC I-
independent mechanism. The first attempt to generate genetically 
engineered T lymphocytes goes back to 1989, when Gross generated a 
functional T cell expressing a chimeric receptor by fusing an antibody 
fragment to TCR constant domain [54]. Further improvements in 
chimeric antigen receptors (CAR) have been achieved in 2nd and 3rd 
generation CAR-T cells by fusing antibody fragments to intracellular 
CD3-zeta (ζ) and additional costimulatory domains like CD28, OX40 
or 4-1BB. As for TILs, CAR-T therapy requires lymphocytes isolation 
from each patient. Ex vivo rescued T cells are engineered to express the 
CAR by viral vectors (retroviral or lentiviral), and reinfused into 
patients. In August 2017, FDA approved the first CAR-T cell treatment 
marked as Kymriah(TM)(tisagenlecleucel) for B cell acute 
lymphoblastic leukaemia. 
• Immune checkpoint inhibitors. Moving beyond the more complex 
technologies of T cell engineering, immune modulation is based on 
reactivation of anergic T-cells by antibodies that block or activate 
regulatory receptors (see next section) (Fig.8). 
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Immune checkpoint landscape; blockade and activation 
The regulation on T cells is the result of a balance between activating and 
repressing stimuli, also called immune checkpoints. As explained above, 
physiologically, T cell activation occurs by interaction with APC through the 
formation of so-called immunological synapse. The latter consists of a 
tripartite interaction among TCR-MHC I/II, adhesion, and 
costimulatory/checkpoints. The main determinant for costimulatory 
interaction is mediated by CD28-CD80 (B7-1)/CD86 (B7-2), respectively, on 
T cells and APC. A full activation of APC by TLRs pathway is required for 
CD80/CD86 expression. Additional late costimulatory signals are afforded by 
CD27, ICOS (CD278), 4-1BB (CD137) and OX40 (CD134) receptors on T 
cells and their ligands on dendritic or stromal cells. On the other side, 
inhibitory receptors are needed to inactivate T cells once the insult is 
eradicated, and to avoid destructive action on healthy tissue of autoreactive 
CTLs. The molecular players of the inhibitory pathways are more 
heterogeneous and involve DCs, stroma cells and Treg [55]. CTLA-4 has been 
the first characterized inhibitory receptor on effector T cells. It is expressed by 
activated effector T cells and binds to CD80/86. Thus, CTLA-4 competes with 
CD28, acting as decoy for CD80/86. The CTLA4-CD80/CD86 interaction 
induces effector T cell shutdown. Treg cells also express CTLA-4, contributing 
to CD80/86 decoy. In addition, as opposite to effector T cells, CTLA-4 signal 
transduction activates Treg inducing their maximal immune-suppressive 
function. Programmed death 1 (PD-1) is an additional inhibitory receptor of T 
cells. Its ligands, PD-L1 and PD-L2, are expressed by APCs. Additional 
inhibitory molecules are BTLA, TIM-3, LAG-3 and TIGIT [56]. Considering 
the equilibrium and escape phases of immunoediting in cancer, inhibitory axis 
overcomes the stimulatory ones, inducing T cell anergy.  
The cellular components responsible for inhibitory TME are:  
• Cancer cells. Cancer cell themselves can develop the ability to express 
inhibitory ligands (i.e. PD-L1, PD-L2) and produce soluble pro-tumour 
factors (i.e. IL-10, VEGF, TGF-β, PGE-2). 
• DCs. Many literature reports highlight that DCs into tumour 
microenvironment have an immature or tolerogenic phenotype. These 
DCs contribute to T cell anergy by expressing low MHC and 
CD80/CD86 with high inhibitory ligands (i.e. PD-L1 PD-L2). 
• Tumour associated macrophages (TAMs). As DCs, TAMs can hijack 
their anti-tumour function to pro-tumour according to M1-M2 
paradigm. The term M1 refers to anti-tumour macrophages expressing 
TNFα and IL-12; whereas M2 macrophages are pro-tumour producing 
IL-10, TGF-β and VEGF. As expected, M2 are the most abundant 
macrophages into TME [57]. 
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• Treg. Regulatory T cells play an essential role in tumour progression 
principally acting as decoy for both receptors (sequestering 
CD80/CD86 by CTLA-4) and soluble factors (sequestering IL-2 by IL-
2r) [58]. 
• Several cell types from tumour microenvironment also contribute to the 
generation of immunosuppression. These actors differ from a tumour 
to another and include principally cancer-associated fibroblasts (CAFs) 
and cancer-associated stromal cells (CASC) but also adipocytes, 
endothelial cells and so on. These cells produce a plenty of 
immunosuppressive molecules including miRNA, cytokines, 
chemokines or matrix remodelling proteins [59,60]. 
 
Based on these considerations, checkpoint-based immunotherapy relies on re-
activation of anergic T cells by agonist or antagonist molecules. Although 
many types of drugs with immunomodulatory effect have been tested, 
including small molecules and aptamers, the most feasible and advanced 
approaches exploit monoclonal antibodies (mAbs) (Fig.8) [61,62]. To date, a 
great deal of mAbs with immunomodulatory activity have been isolated and 
tested preclinically and clinically. This approach allows to rescue the cytotoxic 
activity of weak CTLs acting either as agonists on costimulatory receptors, or 
as antagonists on coinhibitory ones [63]. Until now, FDA and EMA have 
approved mAbs targeting the three main immunosuppressive receptors CTLA4 
(Ipilimumab), PD1 (Nivolumab and Pembrolizumab) and PDL1 
(Atezolizumab, Durvalumab and Avelumab). On a regular basis, regulatory 
agencies extend the approval of these mAbs for the treatment of several tumors 
including melanoma, non-small cell lung cancer (NSCLC), renal cell 
carcinoma (RCC), Head and Neck Squamous Cell Carcinoma, Hodgkin 
Lymphoma, Urothelial Carcinoma, microsatellite instability (MSI)-high or 
mismatch repair (MMR)-deficient solid tumors and Merkel-cell carcinoma 
(MCC). Clinical trials for additional therapeutic indications also arise, every 
year. Despite unprecedent response of immunotherapy, the reported anti-
cancer effect is restricted to a limited percentage of patients, suggesting the 
need for combination therapy or boosting agents. For example, Larkin and 
colleagues studied the effect of Ipilinumab (αCTLA-4) and Nivolumab (αPD-
1) as monotherapy or in combination in advanced melanoma. The objective 
response rate of combination was 57,6% compared to 19% Ipilinumab and 
43.7% Nivolumab monotherapies [64,65]. Additional clinical trials of 
Nivolumab and Ipilinumab combination are still ongoing [66-69]. Despite the 
benefits arising from such combinations, about half of the patients still do not 
respond to therapy. To improve response rate, new antibodies targeting 
secondary inhibitory (TIM-3, VISTA, LAG-3, IDO, KIR) and stimulatory 
(CD40, GITR, OX40, CD137, ICOS) targets recently entered clinical trials 
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[70]. The most promising approach to improve the clinical outcome, could be 
the combination of the well characterized antagonist mAbs (CTLA-4 or PD-
1/PD-L1) to agonist receptors (in particular OX-40) [71,72]. Meanwhile, many 
efforts are dedicated to identify biomarkers for response prediction and the 
molecular basis of resistance to cancer immunotherapy [73]. Today, it is 
acclaimed that a multiparametric value is needed to predict response/resistance 
to immunotherapy, taking into account the principal biomarkers: i) mutational 
load of cancer cells, ii) cancer-immune phenotypes (see previous chapters), iii) 
immune checkpoint molecules expression (i.e. PD-L1, PD-L2, CTLA-4), iv) 
microsatellite instability, v) serum markers (such as lactate dehydrogenase), 
vi) basic and advanced imaging (i.e. immuno-PET) [74]. Considering all this, 
the scientific community is unceasingly interested in isolation of newer and 
more powerful mAbs. 
  
24 
 
 
Fig. 8 Overview of immunomodulatory monoclonal antibodies and armoured chimeric 
antigen receptor (CAR) T cells pathways. In the panel A is shown the negative pathways 
that induce T cells anergy. Such factors include cell surface receptors, such as programmed 
cell death 1 (PD-1), Lymphocyte-activation gene 3 (LAG-3), T cell immunoglobulin and 
mucin domain 3 (TIM-3) and cytokines, such as TGF-β and IL-10. Regulatory T (TReg) cells 
in tumour microenvironment (TME) are involved in the inhibitory mechanisms. In the panel 
B is shown the inhibitory activity of TReg on CAR T cells and on endogenous T cells. The 
immunomodulatory monoclonal antibodies  are used to overcome the immunosuppression 
caused by inhibitory immune checkpoints by blocking suppressive receptors, for example 
programmed cell-death 1 (PD-1) or cytotoxic T-lymphocyte antigen 4 (CTLA-4) and 
activating stimulatory receptors, such as TNFRSF9 (4-1BB) or OX40. The panel D shows the 
pathways for which armoured CAR T cells overcome immunosuppression associated with the 
TME expressing, in the example, CD40L, IL-12 or TNFSF9 (4-1BBL). Image source: Khalil, D. 
N. et al. Nature reviews Clinical oncology. 2016;13(5):273-290. 
25 
 
Structure of monoclonal antibodies and their isolation  
Monoclonal antibodies (mAbs) are the primary tool in clinical use for cancer 
immunotherapy. The structure of Abs consists of a tetramer of two heavy and 
two light chains, linked each other by disulphide bounds. Both heavy and light 
chains contain constant and variable domains. The structure of each Ab is 
composed by a constant crystallisable fragment (Fc) specific to each 
immunoglobulin isotype (IgM, IgA, IgD, IgG, IgE), and the Fab portion 
containing the variable domains responsible of binding to the target (Fig.9). 
Although the hybridoma approach has been used for isolation of new 
monoclonal antibodies for years, it currently suffers from several 
disadvantages, including the need of humanization and no applicability for 
toxic or poorly immunogenic antigens (i.e. highly conserved across species) 
[75]. To overcome these disadvantages, one of the most used technologies to 
isolate mAbs exploits synthetic libraries of single-chain variable fragments 
(scFvs). A scFv consists of variable regions of heavy and light chains in frame-
fused through a flexible linker (Fig.9). These scFvs can be displayed on the 
surface of yeast or phage particles, each of which physically associates its 
genetic information to the corresponding phenotype (i.e., a scFv clone) (Fig.9). 
Phage/yeast display allows to isolate a set of potential binders through several 
selection cycles with the target of interest (recombinant protein or a target 
expressed on cell surface membranes) (Fig.10) [76,77]. 
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Fig. 9 Representation of mAbs, scFv and phage-scFv structure. The immunoglobulins (Ig) 
consist of Fab and Fc portions. Fab contains the variable domains of heavy (VH) and light 
chain (VL) involved in binding to the antigens (blue triangle).  The single chain variable 
fragment is the smallest unit of an antibody able to constitute a paratope and to recognize  its 
epitope. It consists of the variable domain of both heavy and ligth chains fused by a flexible 
linker peptide. In order to create a library of scFv, the mRNA from healty donor spleen is used 
as template to extract by PCR the variable domains, which are then randomly assembled. This 
repertoire of scFv is in frame fused with coat protein PIII of M13 phage. The diversity of 
libraries is usually arround 1010. 
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Fig. 10 Phage display platform. Potentially binder phages are selected on target protein 
throught panning (positive selection). Positive selection step is performed by incubating the 
phages with the target expressing cells or recombinant protein. The negative selection is made 
on target not expressing cells or recombinant protein carrier to eliminate aspecific clones. 
Some selection cycles are performed to enrich the potential binders. At the end of each cycle, 
phages are amplified by E.Coli infection. 
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Combination therapy with Oncolytic viruses 
The limited efficacy of OVs and immune checkpoint modulators has opened 
new possibilities for combination therapies in cancer. As mentioned before, 
much of the effects of oncolytic virotherapy is mediated by cooperation with 
the immune system (cancer vaccine). Namely, one of the most interesting 
features of an OV is to turn immunodeficient tumours (immune-excluded and 
immune desert) in their inflamed counterpart. Moreover, as a consequence of 
OV infection and tumour cell death, the TILs display a more active immune-
phenotype compared to the anergic state of the untreated condition. On the 
other side, cancer immunotherapy has shown its great potential on a restricted 
percentage of patients due to the frequent immunocompromised tumour 
microenvironment. Hence, according to these observations, several preclinical 
models and clinical trials have been developed to get full advantage from both 
OVs and cancer immunotherapy through their “alliance” [78-80] 
 
By using a murine model of glioblastoma multiforme (GBM) and oncolytic 
HSV (oHSV G47Δ expressing mIL-12) Saha and colleagues demonstrated an 
additive effect of OV combination with mAbs targeting PD-1, PD-L1 and 
CTLA-4. Even more interestingly, they showed that the triple combination of 
OV+αPD-1+αCTLA-4 acted synergistically, curing most of GBM in mice and 
conferring complete resistance to tumour re-challenge. Depletion analysis in 
CD4, CD8 or macrophage cell populations suggested a complex cellular cross-
talk and a fundamental role of M1 TAMs [81]. Recently, authors from Amgen 
published the combination of a murine version of T-VEC (OncoVEXmGM-CSF) 
with αCTLA-4, giving particular emphasis to the cure of all injected tumours 
and to the abscopal effect on contralateral lesions dependent on effector CD8 
T cells [82]. Eventually, the first phase 1b clinical trial of T-VEC combination 
with anti PD-1 pembrolizumab has been concluded. Although the endpoint of 
this clinical trial was the evaluation of the safety of combination, the 
preliminary results suggest that combination of T-VEC and pembrolizumab 
could actually overcome the limitations of both single therapies. To address 
this point, a phase III trial is currently ongoing [83]. 
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Aims 
Despite progresses in early diagnostic and care, incidence and prevalence of 
cancer disease is projected to increase in next decades. Indeed, if on one hand 
most people live longer, on the other hand the increased lifespan represents 
itself a “risk factor”, as it rises the exposition to risk factors (lifestyle, genetics, 
environment pollution, etc) inducing an accumulation of mistakes in DNA and 
thus, neoplastic transformation. New antineoplastic drugs have been developed 
for most cancer types, rising up to 50% the survival chances. Nevertheless, 
advanced stages and some cancer types remain killer diseases (i.e. pancreas, 
lung, brain). Immunotherapy has revolutionized the way to treat cancer, 
leading to unprecedented responses in patients and filling gaps in drug 
repertoire for orphan cancer disease. The way to re-activate immune system 
against cancer are many; among these, oncolytic virotherapy and mAbs 
targeting immune checkpoints represent the breakthrough of last decade as 
cancer immunotherapeutics. Despite the preclinical and clinical success of 
OVs and mAbs as monotherapy, the efficacy remains restricted to a small 
percentage of patients, whereas their combination seems to enhance 
significantly each other’s effect. This suggests improved performance of 
combinations, both in terms of safety and efficacy. In particular, most of 
oncolytic viruses currently in clinic or clinical trials are based on: i) attenuated 
vectors with a poor virulence and/or ii) non-attenuated OVs with potential not 
negligible side effects. Likewise, new therapeutic mAbs more powerful of 
those in clinic, and/or against newly discovered immunomodulatory targets are 
required.  
The purpose of my PhD project was to generate a cancer immunotherapeutics 
repertoire to: 
• Overcome the limitations of oncolytic virotherapy, engineering a non-
attenuated HVS-1 with enhanced safety compared to those currently 
developed 
• Study the efficacy and selectivity of these vectors in tumour and normal 
cells. 
• Generate a large repertoire of agonist and antagonist mAbs targeting 
the most relevant immune checkpoint modulators by high throughput 
“immunomic” screening of phage antibody library.  
• Analyse in vitro the potential therapeutic effect of isolated mAbs 
• Generate a proof of principle of advantages in using non-attenuated OV 
in combination to checkpoint inhibitors. 
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Materials and methods 
Cell cultures  
SKOV3 and SAN cells were cultured in RPMI Medium 1640-GlutaMAX™-
I; HEK293 and A375 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium; MRC5 cells were cultured in Minimum Essential Medium Eagle; 
G361 were cultured in Mc Coy’s 5A Medium. All media were supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 50 UI ml-1 penicillin, 50 
µg ml-1 streptomycin, 2mM L-glutamine. All the reagents for cell culturing 
were from GibcoTM, Thermo Fisher Scientific. Cell lines were purchased 
from the American Type Culture Collection (ATCC) or kindly donated from 
collaborators and cultured in a humidified atmosphere containing 5% CO2 at 
37 °C. 
 
SEAP reporter assay 
Data not shown for ongoing evaluation of patentability  
 
Viral rescue and titration by plaque assays or RealTime PCR 
Data not shown for ongoing evaluation of patentability  
 
Modification of BAC-HSV-1 
Data not shown for ongoing evaluation of patentability  
 
VH fragment extraction and sequencing 
After three cycles of panning of phage display scFvs, the double strand DNA 
phagemids containing the scFvs were isolated from cultures of superinfected 
E. coli TG1 cells using GenElute HP Plasmid Maxiprep Kit (Sigma-Aldrich). 
The full length scFvs, containing both VH and VL, were excised by double 
digestion with restriction enzymes BamHI and HindIII (New England Biolabs) 
and purified with Wizard® SV Gel and PCR Clean-Up System (Promega) 
from 1.2% agarose gel. From the purified scFv sub-libraries, a second 
enzymatic excision by NcoI and XhoI (New England Biolabs) was performed 
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to isolate VHs, that were then purified with Wizard® SV Gel and PCR Clean-
Up System (Promega) from a 1.4% agarose gel. Library preparations, 
sequencing and preliminary analysis of the data were performed at the Center 
for Translational Genomics and Bioinformatics, Hospital San Raffaele, 
Milano, Italy. For the preparation of the barcoded libraries, TruSeq ChIP 
sample prep kit (Illumina) was used. A coupling scheme for bar-code was 
implemented, to sequence VHs as a mixture of several sub-libraries. The 
barcoded samples were diluted to a final concentration of 10 pM and 
sequenced with 2×300 SBS kit v3 on an Illumina MiSeq platform. Paired-end 
reads were assembled at the Center for Translational Genomics and 
Bioinformatics, Hospital San Raffaele (Milano, Italy) and the fraction joined 
reads was about 0.9 for each sample. To deeper analyse the data, the unique 
sequences for each sub-library were translated to a protein sequences to 
strengthen the information about enriched paratopes. VH sequences found to 
be enriched in two or more target-specific sub-libraries and stop codon bearing 
VHs were discarded. Sequences were thus sorted according to counts per 
million reads into cycle#3. Ranked VHs were defined as target specific when: 
i) cpm at cycle#3 were ≥85; ii) Δ (cpm cycle#3 - cpm cycle#2) ≥ 0. 
 
Recovery of scFvs of interest from the enriched sub libraries 
PD-1_1, PD-1_2, PD-1_3, PD-1_4, PD-1_5, PD-1_6, PD-L1_1, PD-L1_2, 
PD-L1_3 PD-L1_4, PD-L1_5, LAG-3_1, LAG-3_2, LAG-3_3, LAG-3_4, 
LAG-3_5, LAG-3_6, LAG-3_7, LAG-3_8, LAG-3_9, LAG-3_10 clones were 
isolated from the corresponding cycle#3 sub-library by overlapping PCR. 
Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific) was used 
to perform two extension reactions to obtain firstly single VH and VL 
fragments, and next the full scFv. The overlapping primers were designed 
within the corresponding HCDR3 regions and in constant region of plasmid 
upstream and downstream of VH and VL. The reactions were assembled as 
follow: 150 ng of template (PD-1, PD-L1 or LAG-3 cycle#3) for the first PCR 
amplifying separately VH and VL fragments; 10 ng of template for extension 
PCR to reconstitute the full scFv. Each reaction was performed with 0.5 µL 
Phusion DNA Polymerase (0.02 U/µL); 10 µL 5x Phusion HF Buffer; 1 µL 
dNTP mix; 0.5 µM forward primer; 0.5 µM reverse primer; 1.5 µL DMSO; 
H2O to a final volume of 50 µL. The primer sequences are not indicated for 
protection of intellectual property. The success of the rescue was evaluated by 
Sanger sequencing. 
32 
 
 
 
Antibody production and purification  
For the conversion of the selected scFvs (PD-1_1, PD-1_2, PD-1_3, PD-1_4, 
PD-1_5, PD-1_6, PD-L1_1, PD-L1_2, PD-L1_3 PD-L1_4, PD-L1_5, LAG-
3_1, LAG-3_2, LAG-3_3, LAG-3_4, LAG-3_5, LAG-3_6, LAG-3_7, LAG-
3_8, LAG-3_9, LAG-3_10) into whole IgG4, the VH and VL was amplified 
with specific primers and purified with Wizard® SV Gel and PCR Clean-Up 
System (Promega) by 1.3% agarose gel. The PCR reactions were assembled as 
follows: 30-60 ng of template; 12.5 µL mix PCR; 1.5 µL of 5 µM forward 
primer; 1.5 µL of 5 µM reverse primer; H2O to a final volume of 25 µL. The 
primer sequences are not indicated for protection of intellectual property. In-
Fusion HD cloning kit (Clontech Laboratories, Mountain View, CA, USA) 
was used to insert the variable fragments in vectors expressing the constant 
antibody heavy and light chains. The VHs were cloned in the Peu 8.2 vector, 
previously linearized with BamHI and BssHII (New England Biolabs), and the 
VLs were cloned Peu 4.2 vector, linearized with ApaLI and AvrII (New 
England Biolabs). Stellar Competent Cells (Clontech Laboratories, Inc, 
MountainView,CA, USA) were transformed with obtained vectors and the 
colonies were screened by digestion and sequence analysis. 
The correct preps were co-transfected in HEK293-EBNA by using 
Lipofectamine Transfection Reagent (Life Technologies, Inc.) and grown up 
for about 10 days at 37 °C in serum-free CD CHO medium (Gibco, Life 
Technologies, Inc.) supplemented with 5 ml of L-glutamine 200 mM (Gibco, 
Life Technologies), 5 ml of Penicillin-Streptomycin 10.000 U/mL-10 mg/mL 
(Sigma-Aldirch) in 150mm Corning® tissue-culture treated culture dishes. The 
conditioned media were collected and the antibodies were purified by using 
Protein A HP Spin-Trap or High-trap Protein A HP (GE Healthcare Life 
Sciences, New York, USA).  
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Results 
Generation of oncolytic viruses 
Identification of tumour-selective promoters 
As mentioned before, the restriction of virulence in cancer cells by replication 
conditioning is a prominent advantage in virotherapy. To identify potential 
tumour-specific promoters, I combined reports from scientific literature to 
gene reporter assays.  
Data not shown for ongoing evaluation of patentability  
 
In vitro characterization of tumour-selective promoters and oncolytic 
virus generation 
Thus, by combining literature reports to bioinformatic tools of regulatory 
elements prediction and Encyclopedia of DNA Elements (ENCODE), I 
identified the putative promoter sequences for the three analysed genes. To 
assess the tumour-selective activity I generated reporter gene constructs by 
cloning the selected promoters upstream of the secreted alkaline phosphatase 
cDNA (SEAP). I transfected the reporter vectors into five human tumour cell 
lines of different origin, SAN, G361 and A375 (malignant melanoma), SKOV3 
(ovarian adenocarcinoma), HEK293 (embryonic kidney) and in human normal 
MRC5 cells (normal lung fibroblasts).  
Data not shown for ongoing evaluation of patentability  
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Immunome repertoire generation 
Massive parallel screening and selection of human scFvs targeting immune 
checkpoint inhibitors 
Since the goal on my project was to generate a repertoire of cancer 
immunotherapeutics, we decided to isolate a large collection of human 
antibodies against major Immune Checkpoints (IC), namely, LAG-3, PD-L1, 
PD-1, TIM3, BTLA, TIGIT, OX40, 4-1BB, CD27 and ICOS, in collaboration 
with professor De Lorenzo’s group. To this aim, we developed a novel strategy 
for high throughput sequencing-based screening (HTS) of phage display 
libraries. The main hurdle of this kind of screening is related to “quality” of 
protein target in terms of stability and preserved folding. To bypass this 
limitation, we took advantage of expression of target IC in their native 
conformation on T lymphocytes. Indeed, as explained in introduction, most of 
IC are expressed on T lymphocytes cell surface in response to activation and/or 
stimulation. To exploit this T cell feature, it was set up an activation protocol 
of human peripheral blood mononuclear cells (hPBMCs) to use these cells as 
substrate for the first cycle of selection. The phages eluted from this first cycle 
were potentially enriched for scFvs targeting our target immunomodulators, 
thus henceforth we referred to this sub-library as ‘Immunome Library’. To split 
and enrich phages specific for each target, starting from Immunome Library, 
Fc-fused recombinant proteins were used to perform two subsequent parallel 
cycles of selection. 
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Identification of target specific clones by Next Generation Sequencing and 
mAbs production 
To select individual phage clones targeting each of the ten targets, I combined 
Next generation sequencing technology (NGS) to phage display. This 
approach allows to identify potential binders, according to their enrichment 
profile. In particular, the sequences can be analyzed following the trend of 
enrichment between selection cycles, as well as the representativeness within 
each cycle. Therefore, once selection cycles were performed, I extracted the 
double strand phagemid DNAs from each sub-library. To identify the clones 
of interest, I sequenced the VH regions from extracted DNA by massive 
parallel sequencing on the MiSeq Illumina platform (see Materials & Methods 
Section for details). Obviously, a decrease in complexity of sub-library was 
expected starting from Immunome Library (cycle#1) to target specific cycle#3, 
due to progressive counter selection of non-specific clones and increase in 
preponderance of target specific ones. Considering this, to optimize costs and 
output (i.e. number of reads per sample) I mixed together VH from cycle #2 
and #3 of each target in the same run of sequencing, using two different 
barcodes. On the contrary, I dedicated a whole run of MiSeq to cycle#1 
Immunome Library to achieve the deepest possible coverage. For each target, 
10 to 20 million of reads were obtained. After the sequencing and elimination 
of non-joined sequences performed at the Center for Translational Genomics 
and Bioinformatics, Hospital San Raffaele, I performed an in-depth analysis of 
data. First, I removed from analysis the VH sequences found in two or more 
target-specific sub-libraries, presumably due to the enrichment of Fc binders 
shared by the 10 recombinant proteins (still present, despite the negative 
panning steps). In the same way, the clones without the classical framework 
backbone or encoding stop codons into the scFv sequence, were taken out from 
the list of potential binders, due to biased unspecific biological enrichment 
(Fig.31). I ranked the resulting filtered sequences by representativeness at 
cycle#3 to identify those with the highest level of enrichment. To trap the most 
relevant clones, I introduced a threshold filter of 85 counts per million (cpm) 
at cycle#3. These stringency criteria allowed me to identify the best potential 
binders for 9 out of 10 targets. Indeed, TIGIT selection was not fruitful, 
probably due to weak expression on hPBMCs. In figure 32, the top 10 
sequences for each target were shown in relation to cpm at cycle#2 and #3. In 
addition, by phylogenetic analysis, I evaluated the heterogeneity of the top ten 
binders for each target, named as target_ranking, reported in figure 33 together 
with detailed trend of enrichment from cycle#1 to #3. 
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To demonstrate the effectiveness of the screening, we decided to characterize 
the best scFvs for three out of the nine targets.  
A limitation of HTS approach is that detailed information is obtained 
exclusively for VH sequences. Moreover, since the selection of potential best 
binders was performed in silico, no isolated clones were available. To identify 
the VL linked to VH of interest and to recover “physically” the clones from 
the phage display sub-libraries, I set up a molecular method [131]. I optimized 
a clone-specific PCR protocol exploiting the unicity of hypervariable HCDR3 
sequence (Fig.34) (see also M&M). I started to rescue clones targeting PD-1, 
PD-L1 and LAG-3, considering the clinical relevance of these IC. 
To test the binding of rescued scFvs, I converted them into fully human IgG4 
by sub-cloning VH and VL into eukaryotic expression vectors encoding 
constant domain of heavy and light chains (Fig.35). The heavy and light chain 
coding vectors were co-transfected in HEK293EBNA cells and IgGs were 
purified by affinity chromatography from conditioned media. Starting from the 
top enriched target specific clone, I converted scFvs up to obtain at least five 
effective antibodies for each of the three targets for further characterizations. 
Indeed, some mAbs (i.e. LAG-3_2, LAG-3_4, LAG-3_5, LAG-3_6) were 
excluded from analysis because of low productivity or instability 
(precipitation). 
For all the target proteins, good binders (nanomolar Kds) according to ELISA 
assays were identified. The best mAbs were also assessed for their biological 
activity revealing both the ability to efficiently induce T cell proliferation and 
cytokines production (Ref., Data not shown; from professor De Lorenzo’s 
group). Furthermore, preliminary data suggest a relevant in vivo anti-tumor 
activity of some novel anti-PD1 and anti-PD-L1 mAbs in a mouse preclinical 
model. 
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Fig. 11 Results from application of filters to the sequence frequencies. The image shows 
the different percentage of full length, out-of-frame and shared sequences of scFvs for all 
targets. The full length scFvs are in green, the out-of-frame scFvs are in orange and the scFvs 
shared in more than one target are in red. The targets CD27, OX40 and 4-1BB show a higher 
percentage of full length scFvs. PD-1, BTLA, ICOS and TIM3 show a discrete percentage of 
full length scFvs. LAG-3 and PD-L1 show a higher percentage of out-of-frame sequences. 
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Fig. 12 Snapshot of best ten scFvs per target from immunome screening. The screening 
procedure started from the universal cycle#1 (inner multicolour circle) performed by 
incubation of naive library Delta on activated PBMCs expressing all the target proteins. Each 
section of the pie chart describes the enrichment profiles for the best ten scFvs targeting the 
indicated targets, and scored according to their counts per million values within the second 
and third selection cycles. The lines within each sector connect the individual enrichments, 
obtained after cycle#2 (small circles) and cycle#3 (large circles). Cycles#2 and #3 were both 
performed on the recombinant proteins. 
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Fig. 13 Detailed trends of enrichments and phylogenetic correlations between the top ten 
enriched scFvs for each target protein (see also previous page). For each of the indicated 
targets, the left panel shows the representation of relative enrichments across the three 
selection cycles, assessed as counts per million. On the right side, the dendrograms report the 
phylogenetic clustering of the ten most enriched clones assessed by translated scFv sequences 
(Phylogeny.fr.). 
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Fig. 14 Scheme of molecular rescue of clones of interest from enriched sub-libraries. The 
picture shows the rescue strategy based on overlapping PCR technology. Starting from the top, 
in A, the first step is based on two independent PCR reactions, that amplify separately the 
upstream and the downstream regions of the whole scFv. The fragments obtained from this 
PCRs share an overlapping region within the HCDR3 region. In B, the second step consists 
annealing, elongation and amplification of the overlapping fragments, to re-construct the full 
scFv. The full length scFv is sub-cloned into an expression vector (C). 
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Fig. 15 Conversion of scFv into a full human IgG. The selected scFvs are converted into 
whole human IgGs inserting the variable fragments (orange and green, respectively, for 
variable heavy and light chains) in vectors expressing the constant antibody heavy and light 
chains. The obtained plasmids were co-transfected in HEK293-EBNA and grown up in serum-
free CD CHO medium. Immunoglobulins were purified from conditioned media 10 days after 
transfection by Protein A.  
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Discussion 
The basic research conducted on the relationships between immune system and 
cancer have led, in the past few years, to the rapidly progressing field of cancer 
immunotherapy, revolutionizing the way to treat cancer patients. For sure, 
immune checkpoint modulators have been the main breakthrough of last 
decade in cancer therapy, driving to an incessant rate of approval of 
monoclonal antibodies by regulatory agencies. Despite this, many efforts are 
still dedicated to understand why these immunomodulatory mAbs exhibit only 
a limited efficacy, working in some patients, but not in others. Recent clinical 
outcomes suggest the need to combine IC inhibitors with drugs able to boost 
anticancer immune responses. One of the most promising approach is to induce 
an improved display of cancer-related proteins and tumour-associated 
antigens. 
Meanwhile, in an apparently distinct field, oncolytic viruses have acquired 
rising clinical relevance thanks to the knowhow in engineering tumour-specific 
viral vectors. The skill of oncolytic viruses to induce tumour cell death is well 
established since decades, but the newly characterized immunogenic cell death 
is changing the way to define OVs. Indeed, OVs bring to an “immunologically 
noisy” tumour cell death that induces the display of TAAs, viral proteins and 
cytokines able to recruit immune cells and to revert the immunologically desert 
cancers into inflamed tumours. Thanks to this feature, it is by now 
conventional to define OVs as cancer vaccines. Nevertheless, clinical 
outcomes from T-VEC (Talimogene laherparepvec, Imlygic or OncoVexGM-
CSF) treated patients show a good efficacy on injected tumours, but still 
limited abscopal effect on metastasis, as cancer relapse often happens. Taking 
together the limitations of IC inhibitors and OVs, their combination looks to 
be a foregone approach. In recent preclinical evidences and clinical trials, the 
combination of T-VEC with anti PD-1, PD-L1 or CTLA-4 resulted in an 
amazing drug synergism. 
In this context, I decided to generate a repertoire of cancer immunotherapeutics 
exploiting both OVs and IC modulators. During my PhD I generated a novel 
non-attenuated oncolytic HSV-1, with potentially improved safety compared 
to those in clinic and clinical trials. In our strategy, to generate a non-attenuated 
OV, we decided not to remove genes associated to virulence. To spare normal 
cells and provide the tumour selective killing, removed information for 
ongoing evaluation of patentability. 
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To complete our cancer immunotherapeutic repertoire, I set up a high 
throughput screening (HTS) of a human scFv phage library to isolate 
monoclonal antibodies targeting immune checkpoint molecules LAG-3, PD-
L1, PD-1, TIGIT, TIM3, BTLA, OX40, 4-1BB, CD27 and ICOS. I combined 
an ex vivo screening performed on hPBMCs (expressing ICs) to NGS. This 
approach has allowed us to identify the enriched scFvs targeting immune 
checkpoints in their native conformation. Starting from the selection 
performed on hPBMCs and referred as Immunome Library, to facilitate the 
identification of target specific scFvs, two additional selection cycles were 
performed, in parallel, with the recombinant proteins LAG-3, PD-L1, PD-1, 
TIGIT, TIM3, BTLA, OX40, 4-1BB, CD27 and ICOS. All selections were 
fruitful, with the exception of TIGIT, probably due to its limited expression on 
hPBMCs. A global overview of the screening revealed that, despite for most 
of the targets, the clone enrichments already occurred at cycle#2, their 
representativeness was significantly improved after the third cycle, resulting 
in an easier identification and isolation. This technology allowed us to isolate 
a repertoire of hundreds of scFvs targeting the main immune checkpoint 
pathways LAG-3, PD-L1, PD-1, TIM3, BTLA, OX40, 4-1BB, CD27 and 
ICOS. As proof of principle, scFvs anti LAG-3, PD-1 and PD-L1 were 
converted into fully human IgG4 revealing nanomolar to sub-nanomolar 
affinities for their targets. The validation of biological activity of selected 
mAbs was assessed in comparison to the clinical gold standard Nivolumab, by 
evaluating T-cell proliferation and cytokines secretion. Interestingly, several 
mAbs from our repertoire showed an enhanced activity compared to 
Nivolumab. These results support the conclusion that ex vivo/in silico HTS 
could be a fruitful way for developing clinically relevant mAbs targeting 
immune checkpoints for cancer therapy. 
In conclusion, my work was aimed to obtain molecular repertoires of improved 
vectors for virotherapy, and a wide collection of antibodies for immune 
checkpoint modulation in cancer. Both the endpoints were reached, as shown 
by the in vitro characterizations of the viral constructs, leading to a novel, safe 
and effective OV, and by the proved efficacy of representative mAbs from the 
wide collection, in increasing T-cell proliferation and cytokine secretion. The 
most recent literature, together with preliminary data obtained in our 
laboratories, lends strong support to the initial hypothesis, according to which 
combination of virotherapy with immune checkpoint modulation confers 
undoubted improvements, compared to monotherapy, in innovative cancer 
treatments [78-83]. Thus, the current work represents a solid start point for the 
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identification of the most suitable combinations of our oncolytic virus with 
immunomodulatory mAbs from our repertoire, in preclinical settings of 
investigation. 
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